Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REIMAGINE 2: CagriSema vs semaglutide and cagrilintide in type 2 diabetes
2022-502678-18-00Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2023
- Modality
- Peptides
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial of CagriSema in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to end of treatment. Started Oct 2023; status: completed.
02
Drugs
CagriSema
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2022-502678-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502678-18-00.